Clinical and Translational Allergy, 2022 Background Lebrikizumab is a monoclonal antibody that modulates activity of interleukin‐13. The Phase 3 ACOUSTICS study assessed lebrikizumab efficacy and safety in adolescents with uncontrolled asthma despite standard‐of‐care treatment.
Graham Colin Roberts +2 more
exaly +3 more sources
Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis [PDF]
Acta Dermato-VenereologicaAtopic dermatitis (AD) is driven by type 2 inflammation, with interleukin-13 (IL-13) as one of the central operators. Lebrikizumab is a monoclonal antibody that inhibits IL-13 signalling.
Barbara Kind +32 more
doaj +3 more sources
Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
Dermatology and Therapy, 2023 Introduction IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13 ...
Robert J Benschop +2 more
exaly +4 more sources
Dermatology and TherapyIntroduction The efficacy and safety of lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, were investigated in patients with moderate-to-severe atopic dermatitis (AD) up to 52 weeks in phase 3 trials.
Chaoran Hu +2 more
exaly +3 more sources
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study [PDF]
Dermatology and TherapyIntroduction Patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab need additional therapeutic options. Lebrikizumab’s distinct mechanism of action may provide that alternative treatment.
Jonathan I. Silverberg +23 more
doaj +3 more sources
Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) [PDF]
Dermatology and TherapyIntroduction We report efficacy and safety of lebrikizumab up to 152 weeks (W) of continuous treatment with/without topical corticosteroids in the ADjoin long-term extension study. Methods ADvocate1&2 W16 lebrikizumab responders (Eczema Area and Severity
Emma Guttman-Yassky +13 more
doaj +2 more sources
Use of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Challenging Clinical Scenarios Including Atypical Presentations, Comorbidities, and Tattooed Skin Involvement: Four Case Reports [PDF]
Case Reports in DermatologyIntroduction: Lebrikizumab is a high-affinity IgG4 monoclonal antibody that selectively binds soluble interleukin (IL)-13, approved for the treatment of moderate-to-severe atopic dermatitis (AD).
Mariateresa Rossi +4 more
doaj +2 more sources
Case Report: Differential response to IL-13 inhibition: lebrikizumab following primary tralokinumab failure in atopic dermatitis [PDF]
Frontiers in MedicineBackgroundAtopic dermatitis is a chronic inflammatory skin disorder driven largely by type 2 immune pathways, with interleukin-13 (IL-13) playing a central role in disease pathogenesis.
Shukry Abdi +2 more
doaj +2 more sources
Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice [PDF]
Dermatology and TherapyIntroduction Atopic dermatitis (AD) is a chronic, relapsing inflammatory disease, significantly impacting a patient’s quality of life. To date, a substantial proportion of patients present an insufficient response to available treatment options ...
Nikolaos Stavropoulos +5 more
doaj +2 more sources
Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies [PDF]
Dermatology and TherapyAtopic dermatitis (AD) is a chronically relapsing, complex skin disease characterized mainly by skin lesions and itch. The first-line treatment for patients with AD includes topical therapy, such as topical corticosteroids (TCS) and topical calcineurin ...
Linda Stein-Gold +7 more
doaj +2 more sources